College of Nursing: Cebu Normal University

You might also like

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 5

Republic of the Philippines

CEBU NORMAL UNIVERSITY


Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

DRUG STUDY
Patient’s Initials: PQ__ Date of Admission: October 6, 2021 Diagnosis: Acute Exacerbations of COPD_____
Age: 65 years old Height/Weight: 175 cm/59 kg_____________________ Clinical Intervention: VATS________________
Sex: Male ______Ward: Male Ward Bed No.: 8 Name of Physician: Dr. Villa_ ______________

Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Generic Name: Pharmacologic Pharmacodynamics or General Indication/s: Contraindicated in: (per system preferably) Before Drug Administration:
Ipratropium Classification: Mechanism of Action:  Management of Hypersensitivity to 1. Check the doctor’s order
Salbutamol Anti- Inhibits cholinergic reversible soya, lecithin, or GI: 2. Assess allergy to the drug
cholinergic/beta- receptors in bronchial bronchospasm related food products nausea 3. Caution patient of the different
Trade Name: agonist associated with (eg., soybeans or side effects
smooth muscle, resulting
Combivent obstructive peanuts, and to any RESPIRATORY: 4. Obtain baseline vital signs
Therapeutic in decreased airway diseases component of Duavent 5. Prepare drugs properly at the
Bronchitis, dyspnea,
Minimum Dose: Classification: concentrations of cyclic (eg. bronchial or to atropine and its coughing, right dosage.
4 inhalations per Bronchodilator guanosine asthma)eye derivatives) pneumonia, 6. Administer in a location where
day monophosphate (cGMP). disease bronchospasm, patient can sit comfortably for
Pregnancy Decreased levels of cGMP Hypertrophic pharyngitis, sinusitis, 10–15 min.
Maximum Dose: Category: Patient’s Indication: obstructive rhinitis 7. Make sure that mask fits
6 inhalations per Not applicable produce local
For patients with chronic cardiomyopathy or properly over nose and mouth
day bronchodilation obstructive pulmonary tachyarrythmia Additional adverse and that mist does not flow into
disease on a regular reactions reported in eyes or put mouthpiece into
Patient’s Dose: Pharmacokinetics: inhaled bronchodilator <2% of patients mouth.
Albuterol 2.5 mg Absorption and Distribution: who continue to have include edema,
plus Ipratropium Minimal systemic absorption evidence of fatigue, hypertension, During Drug Administration:
250 mcg (2% for bronchospasm and who dizziness, 1. Verify patient’s identity
inhalation solution; 20% for require a second nervousness, 2. Explain to patient the purpose
Route: inhalation aerosol; 20% bronchodilator paresthesia, tremor, of medication
Inhalation following nasal use). dysphonia, insomnia, 3. Use the bronchodilator first

Certification Date: 1 February 2021


Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 1 of 4
check and type the registration number)

Registration No. 52Q18778


Republic of the Philippines
CEBU NORMAL UNIVERSITY
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

diarrhea, dry mouth, and allow 5 min to elapse


Frequency: Metabolism and Excretion: dyspepsia, vomiting, before using the
q6H Small amounts absorbed are arrythmia, corticosteroid.
metabolized by the liver palpitation, 4. Observe patient and instruct
Availability/Form tachycardia, to:
18 mcg ipratropium Half-life: Salbutamol: 4 hr; arthralgia, angina,  Breathe out before
bromide and 90 Ipratropium: 2 hr increased sputum, pressing your inhaler.
mcg albuterol taste perversion and  Inhale slowly.
Onset: urinary tract  Breathe in through your
Content: Salbutamol: 15-30 minutes; infection/ dysuria. mouth, not your nose.
Ipratropium Ipratropium: 5-15 minutes  Press down on your
bromide Allergic-type reactions inhaler at the start of
(anhydrous) 500 Peak: eg., skin rash, inhalation (or within the
mcg albuterol (as Salbutamol: 2-3 hr; angioedema of the first second of
sulfate) 2.5mg Ipratropium: 1-2 hr tongue, lips and face, inhalation).
urticaria, laryngospasm  Keep inhaling as you
Duration: and anaphylactic press down on inhaler.
Salbutamol: 4-8 hr; reaction have also been  Press your inhaler only
Ipratropium: 3-6 hr reported once while you are
inhaling (one breath for
each puff).
 Make sure you breathe in
evenly and deeply.

After Drug Administration:


1. Monitor vital signs noting
hypotension and an
irregular or abnormal
pulse.

Certification Date: 1 February 2021


Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 2 of 4
check and type the registration number)

Registration No. 52Q18778


Republic of the Philippines
CEBU NORMAL UNIVERSITY
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

2. Monitor for adverse


effects.
3. Wash mask in hot soapy
water; rinse well and allow
to air dry before next use.
4. Maintain a quiet,
comfortable environment
to minimize anxiety and
perhaps decrease
palpitations.
5. Document correctly and
accordingly.

References:
Karch, A. M., & Lynn, P. (2016). Focus on Nursing Pharmacology (7th ed.). Lippincott Williams & Wilkins.
Kizior, R. and Hodgson, K., (2019). Saunders Nursing Drug Handbook 2019. St. Louis, Missouri: Elsevier
Jones & Bartlett Learning. (2019). 2020 Nurse’s Drug Handbook (19th ed.). Jones & Bartlett Learning.
Lippincott Williams & Wilkins. (Producer). (2013). Nursing 2013 Drug Handbook. Philadelphia, Pa.: Lippincott, Williams & Wilkins

Certification Date: 1 February 2021


Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 3 of 4
check and type the registration number)

Registration No. 52Q18778


Republic of the Philippines
CEBu NORMAL UNIvERSITy
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY

Student Name: ROSALES, GWYN A. Year/Section: Date: Score: /30

Directions: Please select the appropriate rating using the following descriptions.

Element Very Satisfacto Needs Comments


Satisfactory ry Improvement
Drug ☐ Accurately presented all of the patient and drug ☐ Accurately presented most of the patient and ☐ Accurately presented some of the patient and
Informati information (name [brand & generic], dosage drug information related to the case. 1 missing drug information related to the case. 2 or more
on (10%) [patient’s dose; min. & max], frequency, route, information or error noted. [2] missing information or errors noted. [1]
availability, contents) related to the case. [3]
Classificati ☐ Accurately presented the classification ☐ Accurately presented the classification ☐ Inaccurately presented the classification
on (therapeutic and pharmacologic) related to the related to the drug but with 1 irrelevant related to the drug. Classification is not relevant
(10%) drug. [3] information or error noted. [2] to the drug. [1]
☐ Accurately presented the indication/s (general ☐ Accurately presented the indication/s related ☐ Inaccurately presented the indication/s related
Indication
& patient- specific) related to the drug. [3] to the drug but with 1 irrelevant information or to the drug. Indication is not relevant to the drug.
(10%)
error noted. [2] [1]
Mechanism Accurately ☐ presented the ☐ Accurately presented the mechanism of ☐ Inaccurately presented the mechanism of action
of Action mechanism of action action of the drug but with 1 irrelevant of the drug. Mechanism of action is not relevant to
(10%)
(pharmacokinetics, pharmacodynamics) of the information or error noted. [2] the drug. [1]
drug. [3]
☐ Accurately presented all of the common ☐ Accurately presented most of the common ☐ Accurately presented some of the common
Contraindicat
contraindications related to the drug. [3] contraindications related to the drug. 1 missing contraindications related to the drug. 2 or more
ion
information or error noted. [2] missing information or errors noted. [1]
(10%)
Side ☐ Accurately presented all of the common side ☐ Accurately presented most of the common ☐ Accurately presented some of the common side
Effects effects related to the drug. [3] side effects related to the drug. 1-2 missing effects related to the drug. 3 or more missing
(10%)
Certification Date: 1 February 2021
Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 4 of 4
check and type the registration number)

Registration No. 52Q18778


Republic of the Philippines
CEBu NORMAL UNIvERSITy
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

information or errors noted. [2] information or errors noted. [1]


Nursing ☐ Accurately presented all of the common ☐ Accurately presented most of the ☐ Accurately presented some of the
Responsibili nursing responsibilities (before, during, and after) common nursing common nursing
ties (30%) related to the drug. [9] responsibilities related to the drug. 1-2 missing responsibilities related to the drug. 3 or more
information or errors noted. [7] missing information or errors noted. [3]
☐ Presented at least 2 sources that are updated ☐ Presented only one source that is updated ☐ No source was presented. Sources are not
Referenc
es (within 5 years), relevant, and credible. [3] (within 5 years), relevant, and credible. Other updated (more than 5 years), relevant, and
(10%) sources are not updated, credible or relevant. credible. [1]
[2]
Sub-score = = =

Evaluated by:

Signature over Printed Name of Clinical Instructor

Certification Date: 1 February 2021


Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 5 of 4
check and type the registration number)

Registration No. 52Q18778

You might also like